Zyban News and Research

RSS
Bupropion (previously known as amfebutamone; Wellbutrin, Zyban) is an atypical antidepressant that acts as a norepinephrine and dopamine reuptake inhibitor, and nicotinic antagonist. Bupropion belongs to the chemical class of aminoketones and is similar in structure to the stimulant cathinone, to the anorectic diethylpropion, and to phenethylamines in general. Initially researched and marketed as an antidepressant, bupropion was subsequently found to be effective as a smoking cessation aid.
USA Medical shares 3 tips to help people stick to New Year's resolutions for better health

USA Medical shares 3 tips to help people stick to New Year's resolutions for better health

Use of nicotine patches or Zyban drug during pregnancy benefits both mother and child

Use of nicotine patches or Zyban drug during pregnancy benefits both mother and child

Study finds sex differences in smoking cessation with medications

Study finds sex differences in smoking cessation with medications

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Smoking cessation medication 46% effective in women

Smoking cessation medication 46% effective in women

New prescription smoking-cessation drug not helping smokers quit

New prescription smoking-cessation drug not helping smokers quit

Women who take stop-smoking drug Zyban during pregnancy give birth to a child with birth defects

Women who take stop-smoking drug Zyban during pregnancy give birth to a child with birth defects

Extending use of bupropion before quitting reduces smoking behavior

Extending use of bupropion before quitting reduces smoking behavior

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Study assesses risk of psychiatric events in patients prescribed smoking cessation drugs

Study assesses risk of psychiatric events in patients prescribed smoking cessation drugs

New editorial offers clarity on confusing drug and alcohol addiction terminology

New editorial offers clarity on confusing drug and alcohol addiction terminology

22nd Century completes enrollment in X-22 Phase II-B smoking cessation study

22nd Century completes enrollment in X-22 Phase II-B smoking cessation study

Anti-obesity drug Contrave may get another chance to prove itself

Anti-obesity drug Contrave may get another chance to prove itself

22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation

22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century submits IND to FDA for VLN cigarettes

22nd Century submits IND to FDA for VLN cigarettes

22nd Century awarded $244,000 QTDP program grant

22nd Century awarded $244,000 QTDP program grant

Smokers with anxiety disorders less likely to quit smoking

Smokers with anxiety disorders less likely to quit smoking

Mylan Pharmaceuticals receives FDA approval for Bupropion HCl ER Tablets

Mylan Pharmaceuticals receives FDA approval for Bupropion HCl ER Tablets

Changing drug therapy can help breast cancer patients get full benefit of tamoxifen treatment

Changing drug therapy can help breast cancer patients get full benefit of tamoxifen treatment